pomegranate seed oil study

effect of pomegranate seed oil on hyperlipidemic subjects: a double-blind placebo-controlled clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138711151640N1

Enrollment

Registered

2009-07-16

Start date

2008-10-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperlipidemia. Disorders of lipoprotein metabolism and other lipidaemias

Interventions

Intervention 1: Pomegranate seed oil capsule, containing 400 mg PSO, twice daily (800 mg PSO) for 4 weeks. Intervention 2: Placebo capsule.

Treatment - Drugs

Placebo

Pomegranate seed oil capsule, containing 400 mg PSO, twice daily (800 mg PSO) for 4 weeks

Placebo capsule

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: serum cholesterol concentrations > 200 mg/dl , serum triglyceride concentration > 150 mg/dl, age more than 20 years, body mass index = 35 kg/m2 Exclusion criteria: being pregnant or lactating, diagnosed allergy and liver dysfunction

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Lipid profile concentration. Timepoint: 1 month. Method of measurement: biochemical measurements on blood sample.	—

Secondary

Measure	Time frame
Hyperlipidemia. Timepoint: 1 month. Method of measurement: biochemical measurements on blood sample.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Parvin Mirmiran

Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University (M.C)

mirmiran@endocrine.ac.ir+98 21 2243 2500

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026